SCHEMBL10021859

SCHEMBL10021859

C=Cc1c2ccccc2cc2ccc(C(=O)OC3CN(COC)C(=O)N(COC)C3)cc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
KDM4E B2RXH2 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HCRTR1 O43613 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NR1I2 O75469 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CCNB2 O95067 3/20 0.31
CDK1 P06493 3/20 0.31
CCNB1 P14635 3/20 0.31
MDH2 P40926 3/20 0.31
CCNB3 Q8WWL7 3/20 0.31
SCARB1 Q8WTV0 1/20 0.31
GSK3B P49841 1/20 0.31
KDM2B Q8NHM5 1/20 0.30
PTGER4 P35408 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10021864 0.83 ALDH1A1 (0.33) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL10021863 0.83 KDM2B (0.33) MEN1KMT2AALDH1A1L3MBTL1KDM2B
SCHEMBL10021857 0.81 ALDH1A1 (0.32) MEN1KMT2AALDH1A1SMN1; SMN2KDM2B
SCHEMBL10021861 0.81 ALDH1A1 (0.32) MEN1KMT2AALDH1A1SMN1; SMN2KDM2B
SCHEMBL472300 0.80 CYP2D6 (0.33) MEN1KMT2AALDH1A1SMN1; SMN2KDM2B
SCHEMBL10021856 0.79 CYP2D6 (0.32) MEN1KMT2AALDH1A1SMN1; SMN2HRH3
SCHEMBL10053096 0.79 KDM2B (0.32) MEN1KMT2AALDH1A1KDM2BCYP2D6
SCHEMBL10021858 0.78 ALDH1A1 (0.38) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL471779 0.77 SMN1; SMN2 (0.38) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL17936648 0.77 ALDH1A1 (0.44) MEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2413192-B1 POLYMERIZABLE MONOMERS SHINETSU CHEMICAL CO (JP) 2016-12-21 EP disclosed
US-8501942-B2 Polymerizable monomers SHIN-ETSU CHEMICAL CO., LTD. (JP) 2013-08-06 US disclosed
US-8501942-B2 Polymerizable monomers SHIN-ETSU CHEMICAL CO., LTD. (JP) 2013-08-06 US disclosed
US-20120029193-A1 POLYMERIZABLE MONOMERS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-02-02 US disclosed
US-20120029193-A1 POLYMERIZABLE MONOMERS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-02-02 US disclosed
EP-2413192-A1 Polymerizable monomers Shin-Etsu Chemical Co., Ltd. (JP) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029193-A1 POLYMERIZABLE MONOMERS C9, CCNA1, H1-0 MEN1 87/4885KMT2A 2389/4885KDM4E 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.